1018833-41-4

Basic information

• Product Name: 3-(4-aminophenyl)-6-chloropyridine
• Synonyms: 3-(4-aminophenyl)-6-chloropyridine
• CAS NO: 1018833-41-4
• Molecular Weight: 204.659
• Mol File: 1018833-41-4.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: 3-(4-aminophenyl)-6-chloropyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(4-aminophenyl)-6-chloropyridine(1018833-41-4)
• EPA Substance Registry System: 3-(4-aminophenyl)-6-chloropyridine(1018833-41-4)

Safety Data

• Hazardous Substances Data: 1018833-41-4(Hazardous Substances Data)

Upstream product

• 53939-30-3 5-bromo-2-chloropyridine 
• 214360-73-3 4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)aniline 
• 69045-79-0 2-choro-5-iodopyridine 
• 1227833-84-2 2-chloro-5-pyridylzinc bromide 
• 540-37-4 p-aminoiodobenzene 
• 106-40-1 4-bromo-aniline 
• 444120-91-6 6-chloropyridin-3-ylboronic acid 

Downstream Products

• 1018833-42-5 N-[4-(6-chloro-3-pyridinyl)phenyl]-2-oxo-1,3-oxazolidine-3-sulfonamide 
• 1018833-40-3 N-[4-(6-chloro-3-pyridinyl)phenyl]-1-phenylmethanesulfonamide 
• 1018833-05-0 N-[4-(6-chloro-3-pyridinyl)phenyl]-N'-[4-(methyloxy)phenyl]sulfamide 
• 1221971-25-0 C₂₀H₁₄ClN₃O₄S 

Relevant articles and documents

Amino-Substituted 2,2′-Bipyridine Ligands as Fluorescent Indicators for ZnII and Applications for Fluorescence Imaging of Prostate Cells

ZnII concentrations in malignant prostate tissues are much lower than in benign or healthy, suggesting that ZnII levels are a potential biomarker for prostate cancer (PCa). Five 2,2′-bipyridine ligands were synthesized containing ami

HETEROCYCLIC CGRP RECEPTOR ANTAGONISTS

The present invention is directed to heterocyclic compounds which are antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which CGRP is involved, such as migraine. The invention is also directed to pharmaceutical composi

Selective inducible microsomal prostaglandin E2 synthase-1 (mPGES-1) inhibitors derived from an oxicam template

Here we describe the SAR of a series of potent and selective mPGES-1 inhibitors based on an oxicam template. Compound 13j demonstrated low nanomolar mPGES-1 inhibition in an enzyme assay. In addition, it displayed PGE2 inhibition in a cell-based assay (0.42 μM) and had over 238-fold selectivity for mPGES-1 over COX-2 and over 200-fold selectivity for mPGES-1 over 6-keto PGF1α.